Cambridge Labs' Xenazine 25mg launched in France
UK drugmaker Cambridge Laboratories says that its France-based partner, OPi SA, has launched Xenazine (tetrabenazine) 25mg, following publication of the reimbursement price granted by the French authorities. The product has been approved for use in the treatment of movement disorders associated with Huntington's disease, and in the treatment of hemiballismus.
Cambridge Labs exclusively licensed the neuroleptic-like agent to OPi in 2003 for commercialization in the domestic market where it was approved in late 2005.
According to the UK firm, approximately 6,000 French citizens suffer from HD, a severe and debilitating neurodegenerative disease. It added that Xenazine is the first product approved for use in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze